{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:09:00Z","timestamp":1791360540905,"version":"4.3.1"},"reference-count":46,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust Veterinary J"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical applications and treatment outcomes using molnupiravir for the treatment of naturally occurring feline infectious peritonitis virus (FIPv).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ninety\u2010two client\u2010owned cats with confirmed or presumptive FIP were retrospectively recruited from 35 veterinary practices, primarily in Australia, between February 2023 and March 2024. Cats were categorised based on treatment received: Cohort A: Molnupiravir treatment: monotherapy, maintenance or rescue therapy; Cohort B: Remdesivir and\/or GS\u2010441524 treatment. Seventy\u2010eight cats were enrolled. Molnupiravir was administered orally for a median of 84\u2009days, at a median dose of 13.3\u2009mg\/kg BID. Remission was defined as the resolution of FIP\u2010related signs with (i) normalisation of serum globulin concentrations and A:G ratio (\u22650.6), or (ii) sustained clinical remission for at least 100\u2009days after stopping anti\u2010viral therapy. Cure rate was defined as the percentage of cats achieving sustained remission, without requiring rescue therapy or experiencing a relapsed disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Molnupiravir monotherapy resulted in a cure rate of 72% (13\/18) while molnupiravir maintenance therapy achieved a cure rate of 86% (25\/29), and molnupiravir utilised as a rescue therapy achieved a cure rate of 100% (7\/7). Treatment with remdesivir\/GS\u2010441524 resulted in a cure rate of 71% (17\/24 cats). Survival analysis revealed no difference in outcomes between cats treated with molnupiravir monotherapy and those treated with remdesivir\/GS\u2010441524. Adverse events associated with molnupiravir therapy included neutropenia, and transient elevations in hepatic enzymes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Molnupiravir demonstrated comparable survival outcomes to remdesivir\/GS\u2010441524 for treating FIP and serves as an accessible, effective option across various presentations, including ocular and neurologic forms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/avj.13433","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T22:43:11Z","timestamp":1744756991000},"page":"339-353","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of feline infectious peritonitis in cats with molnupiravir: clinical observations and outcomes for 54 cases"],"prefix":"10.1111","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2070-0795","authenticated-orcid":false,"given":"TM","family":"Clark","sequence":"first","affiliation":[{"name":"Veterinary Specialist Services  24\/34 Goggs Road Jindalee Queensland 4074 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-5014","authenticated-orcid":false,"given":"SJ","family":"Coggins","sequence":"additional","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, B14 The University of Sydney  Sydney New South Wales 2006 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6745-5931","authenticated-orcid":false,"given":"R","family":"Korman","sequence":"additional","affiliation":[{"name":"Veterinary Specialist Services  1\u201015 Lexington Road Underwood Queensland 4119 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"King","sequence":"additional","affiliation":[{"name":"Veterinary Specialist Services  24\/34 Goggs Road Jindalee Queensland 4074 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6025-194X","authenticated-orcid":false,"given":"R","family":"Malik","sequence":"additional","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, B14 The University of Sydney  Sydney New South Wales 2006 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15091847"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11101209"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11111068"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X221118761"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/104063870201400615"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.7589\/0090-3558-39.3.529"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2009.05.008"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2014.04.017"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14092040"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/01652176.2020.1845917"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X19825701"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro975"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005531"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X17729626"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2018.04.026"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X19835065"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15780"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ani11082257"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13112228"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci10020136"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15081680"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16803"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16804"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X231194460"},{"key":"e_1_2_10_26_1","first-page":"19","article-title":"Treatment of FIP in cats with subcutaneous remdesivir followed by oral GS\u2010441524 tablets","author":"Malik R","year":"2022","journal-title":"Veterinarian"},{"key":"e_1_2_10_27_1","unstructured":"Australian government Therapeutic Goods Administration.Personal import scheme. TGA provisionally approves Merck Sharp & Dohme (Australia) Pty Ltd's oral COVID\u201019 treatment LAGEVRIO (molnupiravir). Available at: TGA provisionally approves Merck Sharp & Dohme (Australia) Pty Ltd's oral COVID\u201019 treatment LAGEVRIO (molnupiravir) | Therapeutic Goods Administration (TGA) (Accessed March 2024)."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102329"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00835-2"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2019.12.002"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02404-21"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01684-5"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00915-w"},{"key":"e_1_2_10_35_1","unstructured":"Australian Veterinary Association: Prescribing Guidelines.'Off\u2010label\u2018 drugs comppounded medicines and Antibiotics. Available at:Australian\u2009Veterinary\u2009Association\u2009|\u2009Prescriptions(Accessed March 2025)."},{"key":"e_1_2_10_36_1","article-title":"A key role for molnupiravir in the management of cats with FIP in Australia","author":"Malik R","year":"2022","journal-title":"Veterinarian"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","unstructured":"CookSE VogelH CastilloDet al.A rational approach to identifying effective combined Anticoronaviral therapies against feline coronavirus. bioRxiv.2020.https:\/\/doi.org\/10.1101\/2020.07.09.195016.","DOI":"10.1101\/2020.07.09.195016"},{"key":"e_1_2_10_38_1","volume-title":"EIDD\u20102801 (Molnupiravir)","author":"FIP Warriors CZ\/SK","year":"2021"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16832"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.17187"},{"key":"e_1_2_10_41_1","unstructured":"TaskerS AddieDD EgberinkHet al.FIP diagnostic tools. Available at: FACTSHEETS & TOOLS for Feline infectious peritonitis (FIP) \u2014 ABCD cats & vets (abcdcatsvets.org) (Accessed January 2024)."},{"key":"e_1_2_10_42_1","unstructured":"PedersenNC.The Long History of Beta\u2010d\u2010n4\u2010Hydroxycytidine and Its Modern Application to Treatment of COVID\u201019 in People and FIP in Cats. Sock it to Fip. Available at: The long history of Beta\u2010d\u2010N4\u2010hydroxycytidine and its modern application to treatment of Covid\u201019\u2026 \u2013 Sock it to fip (sockfip.org) (Accessed October 2023)."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104597"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X231183250"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/jcpa.2001.0501"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.5326\/0460152"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001687"}],"container-title":["Australian Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/avj.13433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:13:07Z","timestamp":1754914387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/avj.13433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/avj.13433"],"URL":"https:\/\/doi.org\/10.1111\/avj.13433","archive":["Portico"],"relation":{},"ISSN":["0005-0423","1751-0813"],"issn-type":[{"value":"0005-0423","type":"print"},{"value":"1751-0813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2024-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}